FDA Approves First Treatment for Rett Syndrome
TUESDAY, March 14, 2023 (HealthDay News) – The U.S. Food and Drug Administration has approved Daybue (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients aged 2 years and older.
Approval was based on results from the phase 3 LAVENDER study in which the efficacy and safety of Daybue was assessed versus placebo in 187 female patients with Rett syndrome (ages 5 to 20 years). Compared with placebo, Daybue was associated with statistically significant improvement for change from baseline in the Rett Syndrome Behaviour Questionnaire total score and the Clinical Global Impression-Improvement scale score at week 12.
The most common side effects were diarrhea (82 percent) and vomiting (29 percent). Daybue is expected to be available in the United States by the end of April 2023.
"As the first FDA-approved drug for the treatment of Rett syndrome, Daybue now offers the potential to make meaningful differences in the lives of patients and their families who have lacked options to treat the diverse and debilitating array of symptoms caused by Rett syndrome," Steve Davis, CEO of Acadia Pharmaceuticals, said in a statement.
Approval of Daybue was granted to Acadia Pharmaceuticals.
Related Posts
Most of Restaurant Menu Must Be Vegetarian Before Meat Eaters Make the Switch
FRIDAY, Dec. 24, 2021 (HealthDay News) -- Meat eaters are far more apt to choose...
La ketamina le gana al electroshock para el alivio de la depresión difícil de tratar
JUEVES, 25 de mayo de 2023 (HealthDay News) -- Un nuevo estudio sugiere que la...
AHA News: 11-Year-Old Heart Defect Survivor Is Living Life Wholeheartedly
TUESDAY, Oct. 11, 2022 (American Heart Association News) -- It started with the...
DMARD Prescribing Low for Older Adults With Rheumatoid Arthritis
MONDAY, April 11, 2022 (HealthDay News) -- Older adults with rheumatoid...